Erratum: Correction to discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors (Journal of Medicinal Chemistry (2015) 58 (2417-2430) DOI: 10.1021/jm501913a);Discovery of potent and selective 8-fluorotriazolopyridine c-met inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 5, 2015, Pages 2417-2430

  Peterson, Emily A ^a   Teffera, Yohannes ^a   Albrecht, Brian K ^a   Bauer, David ^a   Bellon, Steven F ^a   Boezio, Alessandro ^a   Boezio, Christiane ^a   Broome, Martin A ^a   Choquette, Deborah ^a   Copeland, Katrina W ^a   Dussault, Isabelle ^a   Lewis, Richard ^a   Lin, Min Hwa Jasmine ^a   Lohman, Julia ^a   Liu, Jingzhou ^a   Potashman, Michele ^a   Rex, Karen ^a   Shimanovich, Roman ^a   Whittington, Douglas A ^a   Vaida, Karina R ^a   Harmange, Jean Christophe ^a   more..

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [DIFLUORO(3 METHOXYQUINOLIN 6 YL)METHYL] 8 FLUORO[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL]THIAZOLE; 4 [3 [DIFLUORO(QUINOLIN 6 YL)METHYL] 8 FLUORO[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL]THIAZOLE; 5 [3 [DIFLUORO(3 METHOXYQUINOLIN 6 YL)METHYL] 8 FLUORO[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL] 3 METHYLISOXAZOLE; 5 [3 [DIFLUORO(QUINOLIN 6 YL)METHYL] 8 FLUORO[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL] 2 METHYLTHIAZOLE; 5 [3 [DIFLUORO(QUINOLIN 6 YL)METHYL] 8 FLUORO[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL] 3 METHYLISOXAZOLE; 5 [8 FLUORO 3 [1 (3 METHOXYQUINOLIN 6 YL)ETHYL][1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL] 3 METHYLISOTHIAZOLE; 5 [8 FLUORO 3 [1 (QUINOLIN 6 YL)ETHYL][1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL] 3 METHYLISOTHIAZOLE; 5 [8 FLUORO 3 [1 FLUORO 1 (3 METHYOXYQUINOLIN 6 YL)ETHYL][1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL] 3 METHYLISOTHIAZOLE; 5 [8 FLUORO 3 [1 FLUORO 1 (3 METHYOXYQUINOLIN 6 YL)ETHYL][1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL] 3 METHYLISOXAZOLE; 5 [8 FLUORO 3 [1 FLUORO 1 (QUINOLIN 6 YL)ETHYL][1,2,4]TRIAZOLO[4,3 A]PYRIDIN 6 YL] 3 METHYLISOTHIAZOLE; 6 [1 FLUORO 1 [8 FLUORO 6 (1 METHYL 1H PYRAQZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]ETHYL] 3 METHOXYQUINOLINE; 6 [1 [8 FLUORO 6 (1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]ETHYL] 3 METHOXYQUINOLINE; 6 [DIFLUORO[8 FLUORO 6 ( 1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]METHYL] 3 METHOXYQUINOLINE; 6 [DIFLUORO[8 FLUORO 6 (1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]METHYL]QUINOLINE; 6 [DIFLUORO[8 FLUORO 6 (PYRIDIN 2 YL)[1,2,4]TRIAZOLO[4,3 A] PYRIDIN 3 YL]METHYL]QUINOLINE; 6 [[8 FLUORO 6 (1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]METHYL] 3 METHOXYQUINOLINE; 6 [[8 FLUORO 6 (1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]METHYL]BENZO[D]THIAZOL 2 AMINE; 6 [[8 FLUORO 6 (1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]METHYL]QUINOLIN 3 OL; 6 [[8 FLUORO 6 (1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]METHYL]QUINOLINE; 6 [[8 FLUORO 6 (1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]METHYL]QUINOXALINE; 8 FLUOROTRIAZOLOPYRIDINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLUTATHIONE; GLUTATHIONE TRANSFERASE; N [6 [[8 FLUORO 6 (1 METHYL 1H PYRAZOL 4 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDIN 3 YL]METHYL]BENZO[D]THIAZOL 2 YL]ACETAMIDE; PROTEIN INHIBITOR; PYRIDINE DERIVATIVE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; 5-(8-FLUORO-3-(1-(3-(2-METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)(1,2,4)TRIAZOLO(4,3-A)PYRIDIN-6-YL)-3-METHYLISOXAZOLE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; SCATTER FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CRYSTALLOGRAPHY; CYCLIZATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SYNTHESIS; FLUORINATION; HUMAN; HUMAN CELL; IC50; INTRINSIC CLEARANCE; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; CELL PROLIFERATION; DRUG DESIGN; DRUG DISCOVERY; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924714675     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00591     Document Type: Erratum

References (22)

1. Gherardi, E.; Birchmeier, W.; Birchmeier, C.; Vande Woude, G. Targeting MET in cancer: rationale and progress Nat. Rev. Cancer 2012, 12, 89-103
2. Schmidt, L.; Duh, F. M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S. W.; Zhuang, Z.; Lubensky, I.; Dean, M.; Allikmets, R.; Chidambaram, A.; Bergerheim, U. R.; Feltis, J. T.; Casadevall, C.; Zamarron, A.; Bernues, M.; Richard, S.; Lips, C. J.; Walther, M. M.; Tsui, L. C.; Geil, L.; Orcutt, M. L.; Stackhouse, T.; Lipan, J.; Slife, L.; Brauch, H.; Decker, J.; Niehans, G.; Hughson, M. D.; Moch, H.; Storkel, S.; Lerman, M. I.; Linehan, W. M.; Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat. Genet. 1997, 16, 68-73
3. Liu, X.; Yao, W.; Newton, R. C.; Scherle, P. A. Targeting the c-Met signaling pathway for cancer therapy Expert Opin. Invest. Drugs 2008, 17, 997-1011
4. Comoglio, P. M.; Giordano, S.; Trusolino, L. Drug development of MET inhibitors: targeting oncogene addition and expedience Nat. Rev. Drug Discovery 2008, 7, 504-516
5. Cui, J. J. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress J. Med. Chem. 2014, 57, 4427-4453
6. Porter, J. Small molecule c-Met kinase inhibitors: a review of recent patents Expert Opin. Ther. Pat. 2010, 20, 159-177
7. Albrecht, B. A.; Harmange, J.-C.; Bauer, D.; Berry, L.; Bode, C.; Boezio, A. A.; Chen, A.; Choquette, D.; Dussault, I.; Fridrich, C.; Hirai, S.; Hoffman, D.; Larrow, J. F.; Kaplan-Lefko, P.; Lin, J.; Lohman, J.; Long, A. M.; Moriguchi, J.; O'Connor, A.; Potashman, M. H.; Reese, M.; Rex, K. R.; Siegmund, A.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.; Yang, Y.; Zhang, Y.; Bellon, S. F. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase J. Med. Chem. 2008, 51, 2879-2882
8. Boezio, A. A.; Berry, L.; Albrecht, B. K.; Bauer, D.; Bellon, S. F.; Bode, C.; Chen, A.; Choquette, D.; Dussault, I.; Hirai, S.; Kaplan-Lefko, P.; Larrow, J. F.; Lin, M.-H. J.; Lohman, J.; Potashman, M. H.; Rex, K.; Santostefano, M.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.; Yang, Y.; Zhang, Y.; Harmange, J.-C. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6307-6312
9. Silverman, R. B. Drug Metabolism. The Organic Chemistry of Drug Design and Drug Action; Academic Press: New York, 1992; pp 300-301.
10. For a review of kinase inhibitor design, see the following: Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the 'gatekeeper door': exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694
11. Wang, Y.; Sarris, K.; Sauer, D. R.; Djuric, S. W. A simple and efficient automatable one step synthesis of triazolopyridines from carboxylic acids Tetrahedron Lett. 2007, 48, 2237-2240
12. BHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists J. Med. Chem. 2009, 52, 4703-4086
13. Laurence, C.; Gal, J.-F. Thermodynamic and Spectroscopic Scales of Hydrogen-Bond Basicity and Affinity. In Lewis Basicity and Affinity Scales: Data and Measurement; Wiley: New York, 2010; pp 119-135.
14. Incubation of inhibitors with RLM and glutathione led to displacement of the 8-fluorine even in the absence of NADPH. For a review on GSH conjugation see the following: Hayes, J. D.; Pulford, D. J. The glutathione S-transferase supergene family: regulation of GST∗ and the contribution of the isoenzymes to cancer chemoprotection and drug resistance Crit. Rev. Biochem. Mol. Biol. 1995, 30, 445-600
15. Hinson, J. A.; Roberts, D. W.; James, L. P. Adverse Drug Reactions. In Handbook of Experimental Pharmacology; Uetrecht, J., Ed.; Springer: New York, 2010; Vol. 196, Part 3, pp 369-405.
16. Roberge, J. Y.; Yu, G.; Mikkilineni, A.; Wu, X.; Zhu, Y.; Lawrence, R. M.; Ewing, W. R. Synthesis of triazolopyridines and triazolopyrimidines using a modified Mitsunobu reaction ARKIVOC 2007, 12, 132-147
17. Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition Science 2007, 317, 1881-1886
18. For a more detailed description of the methods used in these experiments see the following: Teffera, Y.; Colletti, A. E.; Christophe-Harmange, J.-C.; Hollis, L. S.; Albrecht, B. K.; Boezio, A. A.; Liu, J.; Zhao, Z. Chemical reactivity of methoxy 4-O-aryl quinolines: identification of glutathione displacement products in vitro and in vivo Chem. Res. Toxicol. 2008, 21, 2216-2222
19. For an analysis of electronic properties of various five-membered heterocycles, see the following: Katritzky, A. R.; Pozharskii, A. F. Handbook of Heterocyclic Chemistry, 2 nd ed.; Pergamon: Amsterdam, 2000; p 378.
20. For a discussion of the relationship between c-Met target coverage and tumor growth inhibition, see the following: Yamazaki, S.; Skaptason, J.; Romero, D.; Lee, J. H.; Zou, H. Y.; Christensen, J. G.; Koup, J. R.; Smith, B. J.; Koudriakova, T. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models Drug Metab. Dispos. 2008, 36, 1267-1274
21. Procedure adapted from the following: Lee, S.; Beare, N. A.; Hartwig, J. F. Palladium-catalyzed α-arylation of esters and protected amino acids J. Am. Chem. Soc. 2001, 123, 8410-8411
22. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 1999, 27, 1350-1359